Join us this morning at 11am for the laun... - Leukaemia CARE

Leukaemia CARE

904 members505 posts

Join us this morning at 11am for the launch or the Acute Myeloid Leukaemia (AML) North of England Virtual Support Group


10th August at 11am – Launch meeting – Hosted by Jessica Turner, Leukaemia Care North-West Regional Coordinator.

Our Acute Myeloid Leukaemia (AML) North Virtual Support Group is for anyone who has been diagnosed with AML in the North of England. Our meetings are a great way for you to meet someone who is going through or has been through the same journey as you. .

Guest: Laura de la Harpe, Registered Nutritional Therapist and Nutritionist

If you would like to attend this group, please register your attendance online here.

If you would like further information or if you would like to attend, please contact our Patient Services Team on freephone 08088 010 444 (Monday – Friday, 9am-5pm) or email

2 Replies

My Thoughts on the Future of FLT3 Therapy in AML

CME by Naval G. Daver, MD

Source: Current and Future Treatment Strategies for Acute Myeloid Leukemia


Gain insight on the latest investigative treatments for patients with FLT3-positive AML with this expert commentary.

"Approximately 25% of patients with acute myeloid leukemia (AML) have the FLT3-ITD or FLT3-TKD mutation, which is prognostic for poorer outcomes. In the past 4 years, the FDA approved 2 FLT3 inhibitors, midostaurin and gilteritinib. Midostaurin was approved in combination with standard 3+7 induction chemotherapy, in a randomized, multicentral phase III study of 3+7 with midostaurin vs 3+7 alone in patients with newly diagnosed FLT3-ITD and/or DA35 mutations in the frontline setting. Gilteritinib is a more potent and specific second-generation FLT3 inhibitor and was approved based on improved survival as well as improved composite CR (CRc) rate, noted in the phase III Admiral study in patients with relapsed/refractory FLT3-ITD–mutated and/or D835-mutated AML, in which gilteritinib was compared with investigator choice chemotherapy, and gilteritinib showed a significantly improved CRc rate of 35% vs 15% for chemotherapy."



Sorry I could not make this Hairbear, thanks for letting us know and I hope it went well, take care of yourself.

You may also like...